Keeps Biopharma킵스파마
256940 · KOSDAQ · ₩256940 · 킵스파마
₩5,100▼ ₩210 (3.95%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 17.9% | 22.1% | 13.5% | 13.9% | 7.1% | −18.5% |
| Operating margin | −0.3% | 0.9% | 4.9% | 3.3% | −58.9% | −288.9% |
| Net margin | −5.6% | −5.8% | 0.9% | 4.3% | −77.8% | −359.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +29.6% | +33.4% | +38.5% | +530.3% | +243.1% | — |
| Operating income growth | −138.0% | −74.7% | +103.1% | +135.5% | +30.0% | — |
| Net income growth | −26.6% | −978.8% | −71.7% | +134.6% | +25.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −19.9% | −17.5% | 2.1% | 7.1% | −19.9% | −25.1% |
| Return on assets | −5.6% | −5.2% | 1.1% | 3.4% | −13.5% | −17.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 193.7% | 187.0% | 161.3% | 100.2% | 63.7% | 53.4% |
| Net debt to equity | 74.5% | 68.9% | 49.0% | 58.1% | 8.6% | −17.1% |
| Current ratio | 106.4% | 114.5% | 82.8% | 83.7% | 135.1% | 209.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Keeps Biopharma / 킵스파마 / 256940 / KRX:256940
Source: KRX statistical information